A recent examination of over 25,000 cancer patients admitted to the hospital for FN found no difference between the percentage of low-risk patients (62.1%) and high-risk patients (65.9%) receiving a G-CSF to treat (e.g., therapeutic use) their existing FN [8]. This evidence concerns the gene CSF3 and cancer.